Asker Healthcare Group ASKER.ST
SwedenHealthcare · Medical DistributionNasdaq Estocolmo · SEK
89.70 SEK (+35.4%)
5 analysts
XTB1.00 €affiliateOpen account ↗
Interactive Brokers4.74 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗Interactive Brokers4.74 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Asker Healthcare Group AB is a Swedish distributor of medical products and equipment operating in the healthcare sector, offering supply solutions to hospitals and clinics in the Nordic countries.
Listed on Nasdaq Estocolmo · Symbol ASKER.ST · STO: ASKER · Currency SEK
Key points
from its scores- ✓Strong growth8.7
- ✕Poor share-price trend1.5
- ✕Little or no dividend4.3
- ✕Demanding valuation4.7
AI analysis
bottom line, main risk, context and newsStrong growth and reasonable forward valuation offset weak momentum and moderate leverage, but wait for an improvement in the 52-week range position before entering.
Asker Healthcare shows exceptional growth (revenue +17.5%, earnings +69.8%) with a PEG of 0.56 justifying its forward P/E of 19.53, although its financial health is moderate (ND/EBITDA 3.03) and momentum is weak (26th percentile in 52 weeks).
The main risk is its leverage (Net Debt/EBITDA of 3.03) in a rising-rate environment in Europe, which could increase financing costs and compress its 7.43% operating margin.
Context and risks
No recent relevant news and no material exposure to the current macro context: the company operates in healthcare distribution in Sweden, a non-cyclical sector not dependent on rates, energy, or shipping routes. Its net debt/EBITDA of 3.03 is moderate, but the rate effect is limited and already reflected in quantitative scores.
Is Asker Healthcare Group stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 27% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 37.2 | 26.7 | +39% |
| EV / EBITDA | 16.6 | 14.5 | +14% |
| Price / book | 3.6 | 4.1 | −11% |
| Price / sales | 1.4 | 3.4 | −59% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 4.7 out of 10 (median for Healthcare: 4.7).
Average analyst target: 89.70 SEK, +35.4% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 4.9 (sector 5.5), Growth 8.7 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 37.2
- Forward P/E
- 19.5
- EV / EBITDA
- 16.6
- Price / book
- 3.6
- Price / sales
- 1.4
- PEG
- 0.56
- Market cap
- 25.4B SEK
- Enterprise value
- 31.1B SEK
Profitability
- ROE
- 10.5%
- ROA
- 4.8%
- ROIC (approx.)
- 9.9%
- Gross margin
- 41.3%
- Operating margin
- 7.4%
- Net margin
- 3.8%
- Free cash flow
- 534.4M SEK
- FCF yield
- 2.1%
- Cash conversion
- 28%
Solvency
- Total debt
- 6.5B SEK
- Net debt
- 5.7B SEK
- Cash
- 777.0M SEK
- EBITDA
- 1.9B SEK
- Net debt / EBITDA
- 3.03
- Debt / equity
- 92.26
- Current ratio
- 1.30
- Quick ratio
- 0.77
Growth
- Revenue growth
- +17.5%
- Earnings growth
- +69.8%
- EPS (TTM)
- 1.78 SEK
Dividend
- Dividend yield
- 0.6%
- Payout
- 21.9%
Risk and market
- Analyst consensus
- Buy (5)
- Target price
- 89.70 SEK
- 52-week range
- 56.20 – 95.56
Recent news
All ASKER.ST news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Asker Healthcare Group
Is Asker Healthcare Group stock cheap or expensive?
On P/E and EV / EBITDA, it trades 27% above the Healthcare median on average. Valuation score: 4.7 out of 10 (median for Healthcare: 4.7). Average analyst target: 89.70 SEK, +35.4% versus the price. This is not investment advice.
What score does Asker Healthcare Group get on MeridIAn Screener?
It scores 5.1 out of 10, rank 1,628 of 2,130 (better than 21% of the companies analysed). Its strongest category is Growth (8.7) and its weakest, Momentum (1.5). Analysis of 08/10/2026.
What is Asker Healthcare Group's P/E ratio?
Its P/E is 37.2: the share price equals 37.2 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 19.5.
How much is Asker Healthcare Group worth on the stock market?
Its market capitalisation is 25.4B SEK and its enterprise value, debt included, is 31.1B SEK.
How much debt does Asker Healthcare Group have?
Its net debt (debt minus cash) is 5.7B SEK. That is 3.03 times its EBITDA; the Healthcare median is 1.53.
Does Asker Healthcare Group pay a dividend?
Yes: its dividend yield is 0.59% and it pays out 22% of its earnings.
How has Asker Healthcare Group stock performed over the last year?
It has fallen 21.2% over the last year, excluding dividends. Over the last 52 weeks it has traded between 56.20 and 95.56 SEK. Past performance does not guarantee future results.
What do analysts think of Asker Healthcare Group?
5 analysts cover it; their average recommendation is “Buy” and their average target is 89.70 SEK (+35.4% versus the price). It is an estimate, not market data.